The aim of cancer immunotherapy is the stimulation of immune mechanisms to recognize malignant cells and may be a useful complementary therapy to conventional anticancer therapyImmunotherapy was initiated over 100 years ago when New York surgeon William B. Coley inoculated a bacterial vaccine cons

read more>>

More than $1 million in grants has been approved for five cancer research projects being conducted at The Hormel Institute, University of Minnesota-Mayo ClinicThree grants involve studies related to the prevention, diagnosis and treatment of prostate cancer. The others will perform research relate

read more>>

Pancreatic ductal adenocarcinoma (the disease commonly referred to as pancreatic cancer) carries the worst prognosis of any cancerAs current treatments offer minimal benefit, entirely new approaches are needed. Given the success of local therapies, as opposed to intravenous systemic therapies, for

read more>>

Pancreatic cancer is the 11th commonest cancer in the UK, with around 7,800 new diagnosed cases each year (see CRUK CancerStatsRisk factors include age, family history, mutations in the BRCA2 gene, smoking, fatty and sugary diet, obesity and lack of physical activity. It is one of the least treata

read more>>

NEW YORK -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) today announced the initiation of the pivotal Phase III clinical trial for palifosfamide (ZymafosTM) in patients with front-line metastatic soft tissue sarcomaThe study, called PICASSO 3, is an international, randomized, double-blinded, placebo-co

read more>>

CHAPEL HILL, NC -- Pancreatic cancer is one of the most challenging tumors to treatIdentifying patients who have more aggressive disease could better inform treatment decisions and predict survival prognosis. A new finding from scientists at UNC Lineberger Comprehensive Cancer Center may helpThe

read more>>

There’s nothing worse for parents than seeing their children sufferBut what do parents do when doctors tell them there is nothing that can help make your sick child betterIn October 2007, Chris and Hugh Hempel, of Reno, Nevada, learned that their twin daughters, Addison and Cassidy, have an

read more>>

FRANKFURT -- t2cure GmbH, a biopharmaceutical company developing and marketing stem cell-based regenerative therapies, announced today that the FDA has granted orphan drug designation to t2c001 for the treatment of Buerger's DiseaseThe Company also announced that in a concurrent application in Eur

read more>>

Biovest International, Inc. (Other OTC:BVTI) today announced at the Active Immunotherapeutics Forum in Barcelona, Spain, that the Company is targeting mantle cell lymphoma, in addition to follicular lymphoma, as a next indication for its personalized cancer vaccine, BiovaxID®At the conference,

read more>>

Paris (France) and Laguna Niguel (CA, USA) -- Ipsen (Euronext : FR0010259150; IPN) and Inspiration Biopharmaceuticals, Inc. (Inspiration) announced today that the Committee for Orphan Medicinal Products of the European Medicines Agency has issued a positive opinion on the granting of orphan drug F

read more>>